Cargando…
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients. A total of 210 RT...
Autores principales: | Ravichandran, Rajan, Mohan, Surapaneni Krishna, Sukumaran, Suresh Kumar, Kamaraj, Devakumar, Daivasuga, Sumetha Suga, Ravi, Samson Oliver Abraham Samuel, Vijayaraghavalu, Sivakumar, Kumar, Ramarathnam Krishna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016692/ https://www.ncbi.nlm.nih.gov/pubmed/35440611 http://dx.doi.org/10.1038/s41598-022-10370-1 |
Ejemplares similares
-
Author Correction: An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
por: Ravichandran, Rajan, et al.
Publicado: (2022) -
Molecular docking analysis of the BRCA1 protein with compounds from Justica adhatoda L
por: Jayaraman, Selvaraj, et al.
Publicado: (2020) -
Molecular docking analysis of compounds from Justica adhatoda L with glycogen synthase kinase-3 β
por: Jayaraman, Selvaraj, et al.
Publicado: (2020) -
Molecular docking analysis of phytocompounds from Andrographis paniculata binding with proteins in the notch-signaling pathway
por: Deiva Suga, Sumetha Suga, et al.
Publicado: (2020) -
The porin AaxA protein model from Chlamydia pneumonia
por: Selvaraj, Jayaraman, et al.
Publicado: (2020)